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INTRODUC TION: BACKGROUND AND 
SCOPE
Clinical need for a guideline
Narcolepsy is a disabling hypothalamic disorder that presents with 
a variety of sleep– wake and other symptoms. Excessive daytime 
sleepiness (EDS) is usually the most troublesome feature although 
significantly fragmented and disturbed nighttime sleep (DNS) is 
common with phenomena including sleep paralysis and halluci-
natory experiences around sleep– wake transitions (hypnagogic 
and hypnopompic hallucinations) [1,2]. Whereas narcolepsy with 
typical cataplexy (type 1 narcolepsy, NT1) is considered a distinct 
entity, associated with hypocretin deficiency, narcolepsy without 
cataplexy (type 2 narcolepsy, NT2) is less clearly defined and when 
diagnosed following the current diagnostic criteria is a heteroge-
neous disorder [1]. Although the precise aetiology of narcolepsy is 
unknown, most evidence suggests it is usually a sporadic acquired 
immune- mediated condition that develops in people who are ge-
netically predisposed [2- 5].
Worldwide prevalence estimates suggest that approximately 25– 
50 persons out of 100,000 are affected [6,7]. Some recent studies 
indicate that narcolepsy may be less frequent [8]. Narcolepsy poten-
tially affects every aspect of daily life with considerable personal, 
social and economic consequences. As a result, quality of life mea-
sures of both patients and their families are significantly reduced 
[9,10]. Current treatments include non- pharmacological and phar-
macological approaches [1,11,12].
Treatment guidelines for narcolepsy were first published in 
Europe in 2006 [13] and in the United States in 2007 [14]. Criteria 
for diagnosing narcolepsy into types 1 and 2 (NT1 and NT2) were 
revised in 2014 by the American Academy of Sleep Medicine. A 
recent paper addressed the limitations of the current International 
Classification of Sleep Disorders 3 (ISCD- 3) diagnostic criteria and 
made suggestions for future improvements [15].
Since 2006, there have been considerable developments in our 
understanding of both the aetiopathology and clinical character-
istics in narcolepsy. Furthermore, several new drugs have become 
available. This has prompted the European Academy of Neurology 
(EAN), European Sleep Research Society (ESRS) and European 
Narcolepsy Network (EU- NN) to join forces to provide up- to- date, 
evidence- based recommendations for narcolepsy treatments. 
Patient representatives have been included in the task force, ex-
panding its perspective.
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Summary
Background and aim: Narcolepsy is an uncommon hypothalamic disorder of presumed 
autoimmune origin that usually requires lifelong treatment. This paper aims to provide 
evidence- based guidelines for the management of narcolepsy in both adults and children.
Methods: The European Academy of Neurology (EAN), European Sleep Research Society 
(ESRS) and European Narcolepsy Network (EU- NN) nominated a task force of 18 nar-
colepsy specialists. According to the EAN recommendations, 10 relevant clinical ques-
tions were formulated in PICO format. Following a systematic review of the literature 
(performed in Fall 2018 and updated in July 2020) recommendations were developed 
according to the GRADE approach.
Results: A total of 10,247 references were evaluated, 308 studies were assessed and 
155 finally included. The main recommendations can be summarized as follows: (i) exces-
sive daytime sleepiness in adults— scheduled naps, modafinil, pitolisant, sodium oxybate 
(SXB), solriamfetol (all strong), methylphenidate, amphetamine derivates (both weak); (ii) 
cataplexy in adults— SXB, venlafaxine, clomipramine (all strong) and pitolisant (weak); (iii) 
excessive daytime sleepiness in children— scheduled naps, SXB (both strong), modafinil, 
methylphenidate, pitolisant, amphetamine derivates (all weak); (iv) cataplexy in children— 
SXB (strong), antidepressants (weak). Treatment choices should be tailored to each pa-
tient’s symptoms, comorbidities, tolerance and risk of potential drug interactions.
Conclusion: The management of narcolepsy involves non- pharmacological and pharma-
cological approaches with an increasing number of symptomatic treatment options for 
adults and children that have been studied in some detail.
K E Y W O R D S
cataplexy, European, guideline, management, narcolepsy
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Scope
This guideline focuses on people of any age with a specific diagnosis 
of narcolepsy (NT1 and NT2). It does not address disorders in the 
narcoleptic ‘borderland’ such as idiopathic hypersomnia or any other 
condition causing EDS. Symptomatic treatments of EDS, cataplexy 
and the predominantly nocturnal symptoms of narcolepsy (DNS, 
sleep paralysis, sleep- related hallucinations) are assessed, including 
first- line, second- line and combination therapies. It also evaluates 
pharmacological treatments that are potentially disease modifying 
as well as therapies for a variety of comorbid conditions. The lat-
ter include psychiatric symptoms and fatigue [16], obesity, sleep- 
disordered breathing, rapid eye movement sleep behaviour disorder 
(RBD), restless legs syndrome and periodic limb movements (RLS/
PLMS). Where appropriate, evaluations for adults and children are 
described separately. For some clinical situations, expert statements 
are included. Patients’ view on the management of narcolepsy is also 
included in a special section.
METHODS
The EAN, the ESRS and the EU- NN nominated 18 experts in nar-
colepsy from 11 European countries to form a task force. Four pa-
tient representatives were elected by a patient assembly during the 
European Narcolepsy Day 2018 and were subsequently added to 
the task force to provide an opinion statement around key areas of 
clinical management and research outcomes. Within the task force, 
10 working sub- groups were appointed, each consisting of two ex-
perts responsible for one clinical question.
This guideline was developed in accordance with the recom-
mendations of the GRADE Working Group (https://www.grade 
worki nggro up.org/) and in line with the 2015 practical recom-
mendations for the process of proposing, planning and writing a 
neurological management guideline by EAN task forces [17]. For 
the procedures in detail see the Supporting Information  Appendix 
S1 online.
Following preparatory talks in 2016, the task force was estab-
lished after a signed agreement between the three societies in 2017. 
The guideline production was finalized in September 2020.
Guideline questions
As an initial step, key questions and potential outcomes es-
sential for the clinical management of patients with narcolepsy 
were identified. An explicit list of outcomes for each question 
was proposed by the co- chairs and circulated to the rest of the 
task force working group, prior to rating their relative impor-
tance for clinical decision making. Outcome prioritization was 
undertaken using a 9- point Likert scale and grouped into three 
categories (1– 3, outcome of low importance; 4– 6, outcome 
important but not critical for decision making; and 7– 9, outcome 
critical for decision making). Only outcomes graded as critical 
or important according to expert opinion were subsequently 
analysed. Finally, 10 key questions were formulated and organ-
ized into five sections (see below). The Patients– Intervention– 
Comparator– Outcome (PICO) framework was then used to 
formulate sub- questions, integral to the search strategies and 
draft recommendations. For the exact wording of the PICO 
questions and additional information see the Supporting 
Information and also see below.
PICOs classified into groups and as individual  
questions
Group/topic
1. Are there disease- modifying pharmacological treatments for 
narcolepsy that can restore hypocretin transmission or reverse 
the disease process?
2. Can non- pharmacological treatments improve symptoms of 
narcolepsy?
3. Can pharmacological treatments improve the symptoms of narco-
lepsy in adults?
4. Can any non- pharmacological or pharmacological treatments im-
prove comorbidities and/or quality of life measures in patients 
with narcolepsy?
5. Can pharmacological treatments improve the symptoms of narco-
lepsy in children?
Search strategy
Published studies were identified from the National Library of 
Medicine's MEDLINE database, Elsevier's Embase database and the 
Cochrane Central Register of Controlled Trials by means of specific 
search strategies using a combination of exploded terms and free 
text, focusing on narcolepsy and treatments for narcolepsy. The 
strategy used for MEDLINE was translated to other databases. No 
language or date of publication restrictions were applied. Rarely, if 
studies had distinguished between the differing types of narcolepsy, 
notably NT1 and NT2, this is mentioned in the text. The literature 
search was performed between July and October 2018 and finally 
updated in July 2020. For pharmacological treatments, another up-
date was performed in October 2020.
Data synthesis
A descriptive summary of the included studies with details of 
study design, number and characteristics of enrolled patients, 
intervention(s) and comparator(s), outcome measures and results 
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was first provided in tables and then presented in Summary of 
Findings tables by individual outcome and intervention.
Grading the quality of the evidence and developing 
recommendations
The guideline was developed following the GRADE approach. 
Overall quality of evidence for each outcome was assessed by 
the methodology sub- group (EB, LV). For further details see the 
Method chapters found in the Supporting Information Appendix 
S1 online.
RESULTS
A total of 10,241 references were evaluated for possible inclusion. 
Full texts of 308 studies were assessed with 155 meeting the inclu-
sion criteria. A descriptive summary of the whole process and find-
ings is provided in the Supporting Information Appendix S1. Results 
of the literature search and overall quality of evidence for individual 
PICOs are also provided in the Supporting Information Appendix S1. 
References 35– 173 refer to the Supporting Information.
Search Questions
Group 1 Question(s)— Disease modification
PICO 1
What is the clinical evidence for the efficacy of disease- modifying 
treatments for the remission or improvement of narcolepsy?
Introduction
Preventing total hypocretin neuron loss by an immunomodulatory 
treatment close to disease onset or in highly selected patients or hypo-
cretin replacement therapy (hypocretin, hypocretin analogues, hypo-
cretin receptor agonists) may be considered as a potential treatment 
strategy.
Recommendations – Among the disease modifying treatments eval-
uated none is recommended.
See Table S1.
Future directions/outlook
Specific monoclonal antibody therapies might represent a thera-
peutic option in the future to prevent or slow hypocretin neuron loss. 
The potential for severe side effects of such immune- modulatory 
treatments and uncertainties when to start therapy will require well- 
designed studies in carefully selected narcolepsy populations.
Selective hypocretin receptor agonists are a promising new 
class of drugs. Recently pilot trials on the hypocretin receptor 
agonist TAK- 994 (animal data) and TAK- 925 (adults with NT1) in-
dicated a significant improvement of EDS (with normalization of 
the maintenance of wakefulness test in a few cases of NT1) and 
cataplexy (in animals) [18].
Group 2 Question(s)— Non- pharmacological  
management
PICO 2
What is the clinical evidence of non- pharmacological treatments in 
the management of narcolepsy?
Introduction
Non- pharmacological management of symptom control in nar-
colepsy should always be considered first. Non- pharmacological 
approaches increase patient involvement and enhance self- 
empowerment. Factors such as age, gender, profession, specific life 
situations and comorbidities will influence the potential for using 
non- pharmacological strategies. In some situations where medica-
tion is considered inappropriate such as pregnancy or potentially in 
early childhood, non- pharmacological management approaches are 
mandatory.
Recommendations – We recommend planned daytime naps to im-
prove immediate subjective and objective sleepiness both in drug naïve 
narcolepsy patients and in those taking stimulant medication, at any age.
See Table S2.
Although available evidence on non- pharmacological treat-
ment other than scheduled napping is low, the concept of such ap-
proaches is strongly supported as they promote better acceptance 
of the disease and compliance. Informed scientific knowledge of 
narcolepsy in any patient group is mandatory, including disease 
mechanisms and treatment options. Attempts to implement a fixed 
schedule for nocturnal sleep and daytime activities with short 
scheduled naps during the day are considered important. A general 
healthy lifestyle including regular physical activity and weight con-
trol are also considered important and might be expected to result 
not only in an improvement of symptom control but also enhanced 
patient empowerment. For many patients, joining a patients’ orga-
nization turns out to be of great help as a source of information, 
exchange and support.
Future directions/outlook
Non- pharmacological treatment is considered important and 
forms an initial foundation for managing narcolepsy. Patients often 
have a special interest in non- pharmacological approaches (see 
below) although available scientific evidence for efficacy is very 
limited. Studies evaluating the potentially positive impact of special 
diet, light therapy or exercise programmes are needed.
Group 3 Question(s)— Symptomatic pharmacological 
treatments in adults
General comment: The overall goal of most symptomatic treat-
ments should focus on improving the sleep– wake cycle of narco-
leptic patients with particular attention on daytime performance. 
Improving EDS and reducing cataplexy are typically most important. 
Treatment goals and choice of treatments should take into consid-
eration an individual's pattern of symptoms, preferences and exist-
ing comorbidities.
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PICO 3
What is the clinical evidence for the efficacy of pharmacological 
treatment of EDS and associated features? Is there a difference 
in efficacy between different wake- promoting drugs? What is the 
benefit- to- risk ratio of treatments?
Introduction
Excessive daytime sleepiness is usually the most prominent 
disabling symptom in patients with narcolepsy [1]. EDS can pres-
ent with different phenotypes including sleep attacks, involuntary 
napping, automatic behaviours, an excessive need for sleep (hyper-
somnia sensu strictu), difficulty sustaining attention, and cognitive 
dysfunction. An improvement in EDS is usually assessed by clinical 
history or questionnaires. Objective testing such as the multiple 
sleep latency test (often used for diagnosis) and the maintenance of 
wakefulness test (often used to document treatment response) may 
provide useful information.
Based on several randomized controlled trials (RCTs) and clinical 
experience, there is clear evidence that a number of wake- promoting 
agents and sodium oxybate improve EDS. Treatment choices may 
change over time and be affected by factors such as age, lifestyle, 
severity, tolerance and comorbidities. Clinicians should therefore 
regularly reassess treatment efficacy and safety during follow- up 
visits. Data on long- term efficacy and safety are limited. A recent 
1- year open label single arm pragmatic study supports the long- term 
safety and efficacy of pitolisant for treatment of EDS in patients 
with NT1 and NT2 [19]. However, one- third of patients stopped the 
medication due to lack of efficacy or side effects.
A recent trial performed over 24 months [20] reported a reduc-
tion in body mass index in NT1 patients treated with sodium oxy-
bate, confirming previous clinical observations.
Stimulants (methylphenidate, modafinil, amphetamines and sol-
riamfetol) may increase heart rate and blood pressure with risk of 
hypertension. These potential side effects require careful monitor-
ing and may lead to specific management strategies [21].
Recommendations
See Figure 1 and Table S3.
The lack of head- to- head studies makes comparisons of efficacy 
between different stimulants/wake- promoting drugs difficult. The 
alerting effects of stimulating antidepressants were not evaluated 
as clinical experience suggests any impact on EDS in narcolepsy is at 
best minor. Antidepressants should not be considered as treatments 
for EDS.
Future directions/outlook
New compounds including novel histamine 3 receptor inverse 
agonists and hypocretin receptor agonists may soon become avail-
able for treatment of EDS in NT1 and NT2.
PICO 4
What is the clinical evidence for efficacy of pharmacological treat-
ment of moderate to severe cataplexy? Is there a difference in ef-
ficacy between different drugs? What is the benefit- to- risk ratio of 
treatments?
Introduction
Cataplexy is a pathognomonic symptom of narcolepsy, which is 
reported by 60%– 70% of all narcolepsy patients [1]. In moderate to 
severe cataplexy, pharmacological treatment is usually warranted.
Recommendations
See Figure 1 and Table S4.
Due to a lack of data, comparison of the efficacy of different 
drugs is not possible.
Future directions/outlook
Randomized clinical trials (RCTs) comparing serotonin– 
norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine 
against sodium oxybate to assess the specific benefit- to- risk ratio 
F I G U R E  1  Overview of recommendations and of quality of evidence (adults) (SP, sleep paralysis; HH, hypnagogic/hypnopompic 
hallucinations)
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should be considered. New drugs such as hypocretin receptor ago-
nists may represent a valid option for future treatment of cataplexy.
PICO 5
What is the clinical evidence for efficacy of pharmacological treat-
ment for moderate to severe DNS? Is there a difference in effi-
cacy between different drugs? What is the benefit- to- risk ratio of 
treatments?
Introduction
Nocturnal sleep is significantly disturbed in at least 65% of pa-
tients with narcolepsy. Disruption of sleep maintenance is the most 
common problem with recurring short and long wake periods. Sleep 
onset is usually unaffected. Over 24 h, the total sleep time of a nar-
coleptic person is often within normal limits. The extent of sleep 
fragmentation potentially in association with vivid dreaming and/or 
nightmares, RBD but also RLS/PLMS and sleep- disordered breath-
ing can adversely influence daytime functioning and EDS prompting 
many patients to seek treatment for improving DNS.
Recommendations
See Figure 1 and Table S5.
Future directions/outlook
Different compositions of sodium oxybate e.g., low- salt, and 
long acting formulations may have an additional impact on improve-
ment of DNS and are studied in RCTs. There is a need for more RCTs 
assessing DNS in narcolepsy both for existing drugs and newer 
compounds.
PICO 6
What is the clinical evidence for efficacy of the pharmacological treat-
ment of moderate to severe sleep paralysis and hypnagogic/hypnop-
ompic hallucinations? What is the benefit- to- risk ratio of treatments? 
Is there a difference in efficacy between different drugs?
Introduction
Sleep paralysis and hypnagogic/hypnopompic hallucinations are 
reported by approximately 50% of patients with narcolepsy [1]. No 
RCTs focused primarily on these symptoms and none were appropri-
ately powered to detect efficacy of treatments.
Recommendations
See Figure 1 and Table S6.
Future directions/outlook
There is a need for specific trials on the impact of compounds in-
cluding antidepressants and sodium oxybate on sleep paralysis and 
hypnagogic/hypnopompic hallucinations.
Group 4 Question(s)— Comorbidities
PICO 7
What is the clinical evidence of treatment for psychiatric comorbid 
symptoms?
Introduction
Psychiatric disturbances are frequently present (20%– 30%) 
in narcolepsy, particularly depression and anxiety, potentially as a 
secondary phenomenon reflecting the psychosocial burden of the 
disease [1]. Either near diagnosis or during the course of the illness, 
psychiatric symptoms may require management.
Recommendations
It is suggested that psychiatric disorders in narcolepsy should 
be treated in accordance with general principles for a general 
population. Shared compounds for the symptoms of narcolepsy 
and depression should be considered where appropriate such 
as antidepressants for cataplexy and comorbid mood disorder 
(Weak recommendation). Depressive symptoms need regular re- 
evaluation [22].
The lack of specific studies does not provide support for any par-
ticular treatments for depression in narcolepsy. There is no reason, 
however, to consider well- established treatments for major depres-
sion in the general population to be less effective in narcolepsy.
Future directions/outlook
Specific non- pharmacological approaches including cognitive 
behavioural therapy and pharmacological approaches for psychiatric 
comorbidities in narcolepsy are implicitly needed.
PICO 8
What is the clinical evidence of efficacy and safety for treatment of 
other sleep disorders in narcolepsy such as RBD, sleep- disordered 
breathing, parasomnias, RLS/PLMS? Is there a difference in efficacy 
between different drugs or approaches?
Introduction
A variety of sleep disorders such as RLS (prevalence 10%– 20%), 
sleep apnoea (20%– 40%) or RBD (25%– 70%) are more frequent in 
narcolepsy than in the general population [1]. The underlying aetiol-
ogy of other sleep disorders and their clinical impact on narcolepsy 
remain unclear although specific treatments are often warranted.
Recommendations – Other sleep disorders in narcolepsy should be 
treated in accordance to the general recommendations for their specific 
treatment in non- narcoleptic patients.
See Table S7.
Future directions/outlook
Studies evaluating effects of treatments for other sleep disor-
ders in narcolepsy are needed.
PICO 9
What is the clinical evidence of efficacy for treatments on meas-
ures of quality of life, global improvement or psychosocial factors? Is 
there a difference in efficacy between different drugs?
Introduction
Improving daily performance, quality of life measures and in-
creasing the ability to work are key aims of the management of nar-
colepsy given their severe impact.
Special condition: driving
The ability to drive safely and the adverse effects of EDS are 
often extremely important issues for patients and their families. 
Driving regulations for people suffering from narcolepsy vary be-
tween European countries although successful treatment often al-
lows patients to drive. However, any risk in driving crucially depends 
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on patients recognizing or monitoring their levels of EDS and refrain-
ing from driving if appropriate.
Recommendations
No specific recommendations were provided. Clinical global im-
pression, quality of life and prevention of everyday life risks were 
considered to substantiate the recommendations on symptomatic 
treatments. Single drugs in Table S8 report the synthesis of effect 
on these outcomes.
Future directions/outlook
In future trials, more attention should be given to quality of life 
measures together with other patient reported outcome measures.
Group 5 Question(s)— Symptomatic pharmacological 
treatment in children
PICO 10
What is the clinical evidence for efficacy of pharmacological treat-
ment of any symptom of narcolepsy (including metabolic problems 
such as obesity and precocious puberty) in children? Is there a differ-
ence in efficacy between different treatments?
Introduction
Initial symptoms of narcolepsy occur before the age of 18 in over 
50% of patients [1] and may start at a very young age also before 
puberty onset [23]. The nature of narcoleptic symptoms in childhood 
and adolescence such as cataplexy and EDS differs from the adult 
picture and may change over time [24]. Treatment strategies includ-
ing a non- pharmacological approach are different from adult strat-
egies and require taking into account the developmental aspects. 
Particular attention is needed when evaluating safety and the risk- 
to- benefit ratio of any treatment. Potential treatment side effects 
such as mood disorder and metabolic upset leading to weight gain or 
loss should be proactively assessed.
To date there are no established recommendations for the 
use of narcoleptic drugs when considering pubertal development. 
Endocrinologists who may prescribe adapted treatments in the case 
of advanced puberty should carefully monitor pubertal development.
Recommendations
See Figure 2 and Table S9.
Future directions/outlook
Compounds for the treatment of narcolepsy in children were 
approved only recently, following appropriate trials. The clinical 
efficacy of sodium oxybate for the treatment of EDS and cata-
plexy in children was first reported in 2018. Trials on the safety 
and efficacy of pitolisant in children are yet to be published and 
will start soon for solriamfetol. More studies and approved treat-
ments are needed for the management of children and adoles-
cents with narcolepsy.
Overview of quality of evidence and 
recommendations
See Figures 1 and 2.
PATHWAY, STATEMENTS AND E XPERT 
RECOMMENDATIONS
This guideline provides recommendations that are primarily 
 evidence-based together with opinions from experts. Several clinical 
questions cannot be satisfactorily addressed because of limited evi-
dence and lack of RCTs. Furthermore, firm conclusions are hampered 
by a limited systematic approach to formal assessment of symptoms 
and outcomes using a variety of non- validated and validated measures. 
Almost no head- to- head trials between drugs have been performed.
F I G U R E  2  Overview of recommendations and of quality of evidence (children) (SP, sleep paralysis; HH, hypnagogic/hypnopompic 
hallucinations)
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This part was completed applying an informal method of con-
sensus, based on an extensive literature review, expert opinion and 
discussion. The task force reached consensus and agreed on the fol-
lowing recommendations.
Table S10 provides additional information on the medication.
Pathway for the management of narcolepsy
See Figures 3 and 4.




Experts discussed several particular situations in narcolepsy in the 
absence of any published evidence from formal studies, leading to 
recommendations that are exclusively based upon expert knowl-
edge and experience. The task force reached full consensus for 
these recommendations.
Pregnancy, breastfeeding, and contraception
In the majority of patients, the symptoms of NT1, particularly 
cataplexy, appear to become milder during pregnancy. However, 
there are no prospective studies and only few published retro-
spective studies on this topic [25,26]. Because of the teratogenic 
potential of all drugs used in the treatment of narcolepsy and 
other risks of complications during pregnancy, it is strongly ad-
vised to discontinue all drugs before any planned pregnancy [1]. 
This discontinuation will nearly always have an adverse effect 
on symptom control which can be particularly challenging prior 
to successful conception. If total discontinuation of drug ther-
apy is thought not practicable, it is advised to limit treatment to 
monotherapy.
Of the drugs generally used in narcolepsy, low doses of antide-
pressants seem relatively safe. However, a recent publication has 
raised doubts on the previously assumed safety of modafinil, report-
ing a high prevalence of congenital defects [27]. There are some data 
indicating a positive effect of l- carnitine in a reduction of total nap 
time during the day [28].
The use of medication during breast- feeding in narcolepsy is not 
generally advised.
If a patient has a young child, initiating or restarting sodium oxy-
bate should only be considered if there is a partner or family member 
who can reliably oversee the care of the child at night.
F I G U R E  3  Clinical pathway for the management of narcolepsy (adults)
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Another issue related to pregnancy is the potential pharmacokinetic 
interaction of prescribed medications with oral contraceptives. Most of 
the recommended drugs in the treatment of narcolepsy seem to have no 
relevant interaction. An exception is modafinil, and there is debate about 
pitolisant. The European Medicines Agency advises dose adjustment 
and/or additional measures to prevent pregnancy when initiating modaf-
inil or pitolisant treatment in women using low dose oral contraceptives.
Narcolepsy in the elderly
Clinical experience suggests an improvement of symptoms of narco-
lepsy such as cataplexy and EDS with age. However, DNS often wors-
ens, potentially due to age- related accrual of additional sleep disorders. 
The available evidence on such issues is very limited. It is difficult to 
establish whether the disorder becomes milder or if patients simply 
improve their coping mechanisms over the years. Potentially, there 
may be a less demanding lifestyle after retirement with more planned 
naps, for example. If there are no significant or relevant comorbidities, 
pharmacological treatment of narcolepsy is not age dependent. The 
potential risk of worsening pre- existing cardiovascular disease in the 
elderly age group, particularly with stimulants, may influence treat-
ment options, as may the presence of hypertension [29,30].
In general, reduced levels of activity in old age, with or with-
out comorbidities, may affect the impact of EDS and significantly 
increase its burden. When EDS is adversely affected by inevitable 
behavioural changes associated with age, manipulation of currently 
available drug treatment is rarely successful.
Anaesthesia
There are very few data assessing perioperative risk in NT1 as recently 
concluded by an expert panel [31]. In general, there are no indications to 
suggest that narcolepsy itself is an independent risk factor for surgery 
although, depending on the type of anaesthesia, existing comorbidities 
and medication use may be of concern. Also, sudden discontinuation 
of narcolepsy medication may cause problems but is not necessary for 
most surgical procedures. Some narcolepsy patients can have a longer 
recovery time to wake up from anaesthesia.
Patients refractory to treatment
With an increasing pharmacological arsenal, it is becoming in-
creasingly rare that patients with narcolepsy are truly refractory 
F I G U R E  4  Clinical pathway for the management of narcolepsy (children)
F I G U R E  5  Overview of recommendations of key 
pharmacological treatments (adults)
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to therapy. However, there are large inter- individual differences in 
treatment effect sizes and occurrence of side effects. If a patient ex-
hibits no response whatsoever to a variety of treatments, it is advis-
able to reconsider the diagnosis and clarify precise drug dosing and 
compliance. Also, it should be verified that they have adjusted their 
lifestyle appropriately and are not attempting to use medication to 
compensate for any lack of adjustment. A variety of combination 
therapies are possible in narcolepsy although there is little published 
evidence to guide precise choices.
It should be noted that complete symptom control in narcolepsy 
is relatively rare and medication often serves simply to limit the bur-
den of symptoms such as EDS. In published studies, it is common 
for less than 50% of treated patients to be normalized on subjective 
measures of EDS (Epworth sleepiness scale <11).
Emergencies
In the context of narcolepsy, emergencies are rare, usually relat-
ing to medication- induced intoxication or acute withdrawal effects. 
Regarding the former, the clinical presentation clearly depends on the 
specific medication that has been overused. The latter typically oc-
curs in NT1 when long- term treatment of cataplexy with antidepres-
sant therapy is suddenly discontinued, causing status cataplecticus, 
characterized by long sequences of cataplectic attacks without full 
recovery between episodes [32]. Very rarely, particularly in children, 
the phenomenon can occur spontaneously in the absence of treatment 
changes. The anti- hypertensive drug prazosin is an alpha 1 adrenore-
ceptor antagonist which may also aggravate cataplexy and even induce 
status cataplecticus [33]. Managing status cataplecticus focuses on 
environmental adjustments to avoid potential injuries after falls and 
restarting cataplexy treatment or avoiding precipitating drugs.
PATIENT SEC TION— OPINION STATEMENT
Leontien Sickenga, Madeleine Wallenius, Connie 
Landstedt and Marleny Macario Argueta
Understanding patients’ views and needs is central to developing 
good clinical practice and patient- oriented guidelines. Narcolepsy 
patients’ representatives identified key areas of interest and made 
the following recommendations and suggestions.
1. When enquiring about the various symptoms of narcolepsy, 
physicians should be aware that expressions used by patients 
may diverge from those used by the medical establishment 
and lead to potential inaccuracy. Loose terms such as fatigue 
and tiredness used to describe EDS may cause confusion and 
prompt more detailed interrogation of those symptoms relating 
to excessive sleepiness. Physicians should formulate questions 
openly without leading the patient. For example, when enquir-
ing about cataplexy, a general question such as ‘how do you 
react when you laugh?’ is appropriate. Further, they should be 
able to probe other aspects of narcolepsy outside the core 
symptoms of EDS and cataplexy that may necessitate a fuller 
understanding of sleep– wake disorders and more specialized 
medical training.
2. There is an unmet need for specialized ancillary health workers 
including nurses and psychologists working in sleep centres spe-
cializing in narcolepsy. A nurse, in particular, could focus more on 
practical issues and help manage the daily life of patients as well 
as addressing practical concerns.
3. Measures of treatment success used in clinical trials, for exam-
ple, should be reconsidered. Patient reported outcome measures 
should be incorporated in the individualized management of 
patients.
4. Physicians and specialized nurses should address non- 
pharmacological treatments more fully. Discussion of strategies 
such as regular naps, exercise, good sleeping habits and regular 
schedules are likely to help and additional input from a psycholo-
gist/therapist or dietician may be needed. Patients should also be 
directed to patient organizations and be given advice about ben-
efits and social support when appropriate.
COMMENTS ON RECOMMENDATIONS AND 
FUTURE DIREC TIONS
Narcolepsy typically has a pleomorphic clinical presentation and 
produces a considerable variety of different symptoms with a 
variable clinical course. Prospective and long- term clinical obser-
vational studies would help define the natural course of narcolepsy 
and its variants, improving the development of disease- modifying 
drugs and allowing a better long- term evaluation of symptomatic 
medications.
Although the last 20 years have seen well- designed studies an-
alysing the effectiveness and safety of several symptomatic drugs 
in narcolepsy, some methodological flaws make results difficult to 
transfer to clinical practice or to compare results between studies. 
One issue of concern is that RCTs have had short periods of fol-
low- up, usually limited to around 2 months. In some instances, the 
so- called ‘withdrawal design’ has been applied, exposing the study 
to a high risk of bias. Additionally, older drugs used in narcolepsy 
such as antidepressants and traditional psychostimulants have 
been poorly investigated before the era of controlled studies and 
evidence- based medicine.
Our recommendations for the management of narcolepsy refer 
to the best available evidence and expert experience. Nevertheless, 
amongst patients there is considerable inter- individual variation in 
the efficacy and side effect profile of all commonly used medica-
tions. This necessitates a precise individual treatment plan for each 
patient, contingent on their pattern of symptoms, disease severity 
and comorbid conditions. This may lead to (co- )treatment with sub-
stances that have traditionally been used in the treatment of narco-
lepsy but have not been studied properly in trials.
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It is important to acknowledge that EDS, the usually dominant 
symptom in narcolepsy, has multifaceted expressions including im-
paired attention, poor vigilance and cognitive impairment which 
may be more difficult to treat than unwanted daytime sleep. These 
important expressions may not be adequately assessed if the main 
focus is on sleep. Associated problems such as fatigue may be even 
more refractory to treatment. See the suggested pharmacological 
management algorithm in Figures 3 and 4.
Further information is required on the current armamentarium 
of effective drugs with more head- to- head comparison trials along 
with studies that use drug combinations and a sufficiently long pe-
riod of follow- up. There is also limited information on levels of com-
pliance with current treatments.
Narcolepsy- relevant outcome measures are generally poorly 
correlated with measurements of treatment efficacy used in clin-
ical trials. For example, sleep latency is a common outcome mea-
sure whereas performance measures on attention tasks requiring 
prolonged vigilance may be more informative for activities of 
daily living. Furthermore, by focusing on individual symptoms, 
the overall impact of therapeutic interventions on narcolepsy 
is not properly addressed. There is therefore a need for vali-
dated disease severity scales along with global measures of how 
the disease impacts on quality of life that incorporate patient- 
reported outcomes. Patient involvement in the development of 
these measures is recommended. The Narcolepsy Severity Scale 
is a recently described first attempt to assess narcolepsy symp-
toms in one single scale [34]. This may have utility in the quanti-
fication of narcoleptic symptoms when monitoring or optimizing 
management strategies.
There is a significant lack of clinical trials investigating the whole 
spectrum of pharmacological treatments for narcolepsy in chil-
dren and other groups potentially meriting special consideration 
such as pregnant women and the elderly. This also applies to non- 
pharmacological approaches including special diets, regular exercise 
and scheduled naps, for example.
Finally, preliminary clinical and pre- clinical data from studies 
investigating hypocretin receptor agonists appear promising and 
could potentially herald a new approach to treatment in narco-
lepsy. Other potential techniques to restore hypocretin levels 
such as stem cell replacement or gene therapy remain experi-
mental. Following on from recent studies that have expanded our 
knowledge of the immune basis of narcolepsy, more specific im-
munomodulatory treatments close to disease onset are likely to 
be fruitful in the development of much needed disease- modifying 
therapy.
ADDITIONAL INFORMATION
Table S10 given an overview of medication (titration sched-
ule, mechanism of action, dosage, half- life, European Medicines 
Agency approval, possible treatment combinations) for narcolepsy 
in adults.
GUIDELINE UPDATE
The present guideline will be updated in 5 years. In the case of major 
changes in the evidence on the existing benefits and harms of in-
cluded interventions or if new interventions become available, this 
update could be approached earlier.
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